ELSALYS BIOTECH and the prestigious German cancer research institute DKFZ initiate the development of ELB021 in B-Cell leukemia with the support of EU
July 18, 2017 14:18 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ELSALYS BIOTECH and the prestigious...
ELSALYS BIOTECH et le prestigieux institut allemand de recherche sur le cancer DKFZ initient le développement d'ELB021 dans la leucémie à cellules B avec le soutien de l'Union Européenne
July 18, 2017 14:18 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ELSALYS BIOTECH et le prestigieux...
Elsalys Biotech expands its team to strengthen its strategy and the development of its programs
January 30, 2017 02:34 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ELSALYS BIOTECH EXPANDS ITS TEAM TO...
L'équipe d'Elsalys Biotech s'étoffe pour conforter sa stratégie et le développement de ses programmes
January 30, 2017 02:34 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
L'ÉQUIPE D'ELSALYS BIOTECH S'ÉTOFFE...
ElsaLys Biotech acquires rights of Transgene's anti-CD115 antibody
December 15, 2016 15:12 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Initially developed by TRANSGENE, one...
ELSALYS BIOTECH ÉTEND SES DROITS SUR CD160
February 16, 2016 11:00 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ELSALYS BIOTECH ÉTEND SES DROITS SUR...
ELSALYS BIOTECH EXPANDS ITS RIGHTS ON CD160
February 16, 2016 11:00 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ELSALYS BIOTECH EXPANDS ITS RIGHTS ON...
ElsaLys Biotech announces the completion of the first instalment of a total fundraising amounting to EU 5 million
November 03, 2015 03:35 ET
|
Elsalys Biotech
LYON and ILLKIRCH-GRAFFENSTADEN, France, Nov. 3, 2015 (GLOBE NEWSWIRE) -- ElsaLys Biotech, a biopharmaceutical company dedicated to the development of "best-in-disease" therapeutic antibodies for...
ElsaLys Biotech announces the completion of the first instalment of a total fundraising amounting to € 5 million
November 03, 2015 03:30 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ElsaLys Biotech announces the...
ElsaLys Biotech annonce la réalisation de la première tranche d'une levée de fonds de 5 millions d'euros
November 03, 2015 03:30 ET
|
Elsalys Biotech
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
ElsaLys Biotech annonce la...